Akorn, Inc. (AKRX) Misses Q2 EPS by 1c, Comments on Q3 Revenues

July 30, 2007 4:02 PM EDT

Akorn, Inc. (NASDAQ: AKRX) reports a Q2 loss of $0.05, 1 cent worse than estimates. Revenues were $11.6 million vs. $13.25 million consensus.

In the third quarter 2007, our expectation is to increase quarterly revenues by at least 50% as compared to the current quarter. This is based on the re-launch of IC-Green(TM), which requires us to successfully pass a pre-approval inspection at our Decatur manufacturing facility, the commercial launch of Tetanus Diphtheria Vaccine, and the launch of our Advanced Vision Research contract manufacturing agreement for TheraTears®." (Q3 revenue consensus is $23.4 million)


Related Categories

Earnings
Guidance

Stocks Mentioned

AKRX 1.13

-0.05 -4.24%
Volume: 1,635,783
Track AKRX


Add Your Comment